ATHA Stock Recent News

On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has provided investors with an update on its 2024 exploration programs at its uranium projects. At its Gemini project in the Athabasca Basin, Saskatchewan, the company in late August kicked off a Phase 3 diamond drill program to expand the footprint of mineralization, targeting the down-dip extents of the Gemini Mineralized Zone (GMZ).

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced on Tuesday that it has signed a non-binding letter of intent (LOI) with Australian-listed Terra Uranium Ltd (ASX:T92) for a potential joint venture on key uranium exploration projects in Saskatchewan's Athabasca Basin. The proposed deal involves an option for Terra Uranium to acquire a 70% interest in ATHA's Spire and Horizon properties, while ATHA could gain up to a 60% stake in Terra Uranium's Pasfield Lake property.

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2024, and provided recent pipeline and business updates.

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) said its 2024 exploration program at the Angilak project has successfully expanded the uranium mineralization footprint with a 100% hit rate. The company updated on the progress of its 2024 exploration program at the Nunavut project, with the first six drill holes successfully expanding the footprint of uranium mineralization outside the historic Lac 50 Uranium Deposit.